news
Scientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
List view / Grid view
Drug Discovery Processes
news
UC Davis researchers achieve total synthesis of ibogaine
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
article
New study links type 2 diabetes to accelerated cognitive decline
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
news
Azenta’s BioArc Ultra powers UK research
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
news
Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
article
Promising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
news
AI designs peptides for ‘undruggable’ diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
webinar
The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing
29 January 2025 | By Eurofins Discovery
Explore how a Weight of Evidence (WoE) approach uses in vitro methods and artificial intelligence (AI) to transform carcinogenicity risk assessment, reducing reliance on animal studies while enhancing compliance with FDA and ICH guidelines.
news
First patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
article
New study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
news
New study shows CGM data can predict diabetes complications
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
news
The Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
news
UVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
news
Bio-Rad introduces mixed-mode resin for biomolecule purification
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
webinar
The rise of organoids: a new era in drug discovery
17 January 2025 | By Drug Target Review
This webinar covers how organoids are reshaping drug discovery by providing more accurate models for disease research and drug testing, offering new solutions to long-standing challenges in the industry.
